PDF(Pubmed)
Abstract：
Virtual reality (VR) is an evolving technology that is becoming a common treatment for pain management and psychologic phobias. Although nonimmersive devices (e.g., the Nintendo Wii) have been previously tested with patients on hemodialysis, no studies to date have used fully immersive VR as a tool for intervention delivery. This pilot trial tests the initial safety, acceptability, and utility of VR during maintenance hemodialysis treatment sessions-particularly, whether VR triggers motion sickness that mimics or negatively effects treatment-related symptoms (e.g., nausea).
Patients on hemodialysis (n=20) were enrolled in a phase 1 single-arm proof-of-concept trial. While undergoing hemodialysis, participants were exposed to our new Joviality VR program. This 25-minute program delivers mindfulness training and guided meditation using the Oculus Rift head-mounted display. Participants experienced the program on two separate occasions. Before and immediately after exposure, participants recorded motion-related symptoms and related discomfort on the Simulator Sickness Questionnaire. Utility measures included the end-user\'s ability to be fully immersed in the virtual space, interact with virtual objects, find hardware user friendly, and easily navigate the Joviality program with the System Usability Scale.
Mean age was 55.3 (±13.1) years; 80% male; 60% Black; and mean dialysis vintage was 3.56 (±3.75) years. At the first session, there were significant decreases in treatment and/or motion-related symptoms after VR exposure (22.6 versus 11.2; P=0.03); scores >20 indicate problematic immersion. Hemodialysis end-users reported high levels of immersion in the VR environment and rated the software easy to operate, with average System Usability Scale scores of 82.8 out of 100.
Patients on hemodialysis routinely suffer from fatigue, nausea, lightheadedness, and headaches that often manifest during their dialysis sessions. Our Joviality VR program decreased symptom severity without adverse effects. VR programs may be a safe platform to improve the experience of patients on dialysis.
Patients on hemodialysis (n=20) were enrolled in a phase 1 single-arm proof-of-concept trial. While undergoing hemodialysis, participants were exposed to our new Joviality VR program. This 25-minute program delivers mindfulness training and guided meditation using the Oculus Rift head-mounted display. Participants experienced the program on two separate occasions. Before and immediately after exposure, participants recorded motion-related symptoms and related discomfort on the Simulator Sickness Questionnaire. Utility measures included the end-user\'s ability to be fully immersed in the virtual space, interact with virtual objects, find hardware user friendly, and easily navigate the Joviality program with the System Usability Scale.
Mean age was 55.3 (±13.1) years; 80% male; 60% Black; and mean dialysis vintage was 3.56 (±3.75) years. At the first session, there were significant decreases in treatment and/or motion-related symptoms after VR exposure (22.6 versus 11.2; P=0.03); scores >20 indicate problematic immersion. Hemodialysis end-users reported high levels of immersion in the VR environment and rated the software easy to operate, with average System Usability Scale scores of 82.8 out of 100.
Patients on hemodialysis routinely suffer from fatigue, nausea, lightheadedness, and headaches that often manifest during their dialysis sessions. Our Joviality VR program decreased symptom severity without adverse effects. VR programs may be a safe platform to improve the experience of patients on dialysis.
摘要：
虚拟现实（VR）是一种不断发展的技术，正在成为疼痛管理和心理恐惧症的常用治疗方法。尽管非沉浸式设备(例如，NintendoWii)之前已经对血液透析患者进行了测试，迄今为止,还没有研究使用完全沉浸式VR作为干预交付的工具.这个试点试验测试了最初的安全性，可接受性,和VR在维持性血液透析治疗期间的实用性-特别是，VR是否引发模仿或负面影响治疗相关症状的晕动病(例如，恶心)。
血液透析患者（n=20）被纳入1期单臂概念验证试验。在接受血液透析时，参与者接触到我们新的JovialityVR程序。这个25分钟的程序使用OculusRift头戴式显示器提供正念训练和引导冥想。参与者在两个不同的场合体验了该计划。在暴露之前和之后，参与者在模拟器疾病问卷上记录了与运动相关的症状和相关的不适.实用措施包括最终用户完全沉浸在虚拟空间中的能力，与虚拟对象交互，发现硬件用户友好，并使用系统可用性量表轻松导航Joviality程序。
平均年龄为55.3(±13.1)岁;80%为男性;60%为黑人;平均透析年份为3.56(±3.75)岁。在第一届会议上，VR暴露后,治疗和/或运动相关症状显著减少(22.6对11.2;P=0.03);评分>20表示浸泡有问题.血液透析最终用户报告说，他们高度沉浸在VR环境中，并认为该软件易于操作，系统可用性量表的平均得分为100分中的82.8分。
血液透析患者通常会出现疲劳，恶心,头昏眼花,以及在透析过程中经常出现的头痛。我们的JovialityVR程序降低了症状的严重程度，没有不良影响。VR程序可能是改善患者透析体验的安全平台。
血液透析患者（n=20）被纳入1期单臂概念验证试验。在接受血液透析时，参与者接触到我们新的JovialityVR程序。这个25分钟的程序使用OculusRift头戴式显示器提供正念训练和引导冥想。参与者在两个不同的场合体验了该计划。在暴露之前和之后，参与者在模拟器疾病问卷上记录了与运动相关的症状和相关的不适.实用措施包括最终用户完全沉浸在虚拟空间中的能力，与虚拟对象交互，发现硬件用户友好，并使用系统可用性量表轻松导航Joviality程序。
平均年龄为55.3(±13.1)岁;80%为男性;60%为黑人;平均透析年份为3.56(±3.75)岁。在第一届会议上，VR暴露后,治疗和/或运动相关症状显著减少(22.6对11.2;P=0.03);评分>20表示浸泡有问题.血液透析最终用户报告说，他们高度沉浸在VR环境中，并认为该软件易于操作，系统可用性量表的平均得分为100分中的82.8分。
血液透析患者通常会出现疲劳，恶心,头昏眼花,以及在透析过程中经常出现的头痛。我们的JovialityVR程序降低了症状的严重程度，没有不良影响。VR程序可能是改善患者透析体验的安全平台。
